Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MIST |
---|---|---|
09:32 ET | 1101 | 1.39 |
09:34 ET | 300 | 1.4 |
09:36 ET | 877 | 1.41 |
09:38 ET | 900 | 1.41 |
09:39 ET | 450 | 1.405 |
09:41 ET | 2800 | 1.41 |
09:43 ET | 100 | 1.39 |
09:50 ET | 500 | 1.4017 |
09:52 ET | 1223 | 1.41 |
09:57 ET | 100 | 1.39 |
09:59 ET | 393 | 1.41 |
10:01 ET | 500 | 1.405 |
10:03 ET | 248 | 1.405 |
10:10 ET | 100 | 1.39 |
10:19 ET | 7000 | 1.41 |
10:21 ET | 100 | 1.39 |
10:24 ET | 100 | 1.39 |
10:32 ET | 1000 | 1.3903 |
10:33 ET | 2083 | 1.39 |
10:37 ET | 100 | 1.39 |
11:00 ET | 100 | 1.39 |
11:04 ET | 600 | 1.39 |
11:13 ET | 100 | 1.39 |
11:15 ET | 100 | 1.391 |
11:24 ET | 1000 | 1.39 |
11:26 ET | 100 | 1.39 |
11:31 ET | 892 | 1.3938 |
11:38 ET | 100 | 1.4 |
11:40 ET | 100 | 1.39 |
11:45 ET | 1000 | 1.395 |
11:56 ET | 100 | 1.39 |
12:00 ET | 100 | 1.39 |
12:03 ET | 100 | 1.39 |
12:32 ET | 100 | 1.4 |
12:34 ET | 1125 | 1.39 |
12:38 ET | 100 | 1.39 |
12:39 ET | 1100 | 1.391 |
12:50 ET | 100 | 1.39 |
12:57 ET | 100 | 1.395 |
12:59 ET | 300 | 1.4 |
01:08 ET | 800 | 1.3999 |
01:10 ET | 100 | 1.39 |
01:12 ET | 100 | 1.39 |
01:21 ET | 100 | 1.395 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Milestone Pharmaceuticals Inc | 75.1M | -1.1x | --- |
Barinthus Biotherapeutics PLC | 71.4M | -1.0x | --- |
Entera Bio Ltd | 74.1M | -7.1x | --- |
Tiziana Life Sciences Ltd | 76.3M | -5.4x | --- |
Bioatla Inc | 76.5M | -0.6x | --- |
Chimerix Inc | 78.7M | -1.0x | --- |
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $75.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.65 |
EPS | $-1.25 |
Book Value | $0.50 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.